Researchers have identified that disrupted calcium (Ca²⁺) homeostasis drives cellular aging, with a study published in Nature Communications demonstrating that the antidepressant mianserin can extend both median and maximum lifespans in mice. By blocking the IP3R calcium release channel in the endoplasmic reticulum, the treatment reduces inflammation and restores DNA repair mechanisms linked to the protein PARP1.
How does calcium disruption trigger the aging process?
Cells rely on precise calcium levels to regulate signaling pathways. According to the study led by researchers including W. Xiang and Y. Zhang, a breakdown in this balance—specifically a leak of calcium from the endoplasmic reticulum (ER) into the cytoplasm—is a hallmark of both Hutchinson-Gilford progeria syndrome (HGPS) and natural aging. In progeroid mice, the team found that the protein S100A6 becomes overexpressed, which in turn destabilizes the vital DNA-repair enzyme PARP1. When PARP1 levels drop, DNA fragments escape the nucleus, triggering the cGAS-STING inflammatory pathway, which accelerates cellular senescence.
The researchers identified that S100A6 elevation is not just a feature of genetic progeria. It also appears in the skin fibroblasts of elderly human patients, suggesting that the calcium-leak mechanism may be a fundamental driver of physiological aging in the general population.
Can antidepressants reverse signs of aging?
Mianserin, a long-established antidepressant, has shown potential in mitigating these aging markers. By antagonizing serotonin receptors that activate the IP3R channel, mianserin effectively plugs the calcium leak. In experiments, progeroid mice treated with the drug from four weeks of age experienced a 30% extension in median survival. Furthermore, naturally aged mice treated with the drug for four months showed physical improvements, including increased body size, better locomotion, and reduced spinal curvature compared to control groups.
Comparative Data: Treatment Outcomes
| Model | Intervention | Median Lifespan Extension |
|---|---|---|
| Progeroid Mice | Mianserin | ~30% |
| Naturally Aged Mice | Mianserin | 17.5% |
What are the limitations of the current research?
While these results are significant, the authors of the Nature Communications study note several constraints that prevent immediate clinical application. The cohort of naturally aged mice was small—comprising only seven or eight animals per group—and consisted entirely of males. Additionally, the control mice in the study exhibited relatively low lifespans, a known variable in longevity research that can influence how data is interpreted. As highlighted by Pabis et al. (2024) in Ageing Research Reviews, the “900-day rule” underscores how short-lived control groups can complicate the assessment of anti-aging interventions.
When evaluating longevity studies, look for both lifespan and healthspan metrics. In this study, the physical improvements—such as restored muscle function and bone health—provide essential context that supports the survival data.
Frequently Asked Questions
Is mianserin an approved anti-aging treatment?
No. Mianserin is currently approved for the treatment of depression. Its use for longevity is restricted to experimental models in preclinical research.
How does the calcium leak affect DNA?
The leak leads to the degradation of PARP1, an enzyme necessary for DNA repair. Without sufficient PARP1, DNA breaks accumulate and fragments escape the nucleus, causing chronic inflammation.
Why was mianserin chosen over other drugs?
Initial experiments used 2-APB to block the calcium leak, but the drug caused tremors in the mice. Mianserin provided a more tolerable alternative that achieved similar therapeutic effects without the same side-effect profile.
This report is based on independent scientific findings. To support our ongoing coverage of longevity research and geroscience, consider subscribing to our newsletter or contributing to our non-profit foundation. Have questions about this study or other aging research? Join the conversation in the comments below.
